Resectable Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma : Which Patients Benefit from Adjuvant Radiation Therapy and How Much?

Joint Authors

Donaldson, Sarah S.
Million, Lynn

Source

ISRN Oncology

Issue

Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-6, 6 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2012-03-15

Country of Publication

Egypt

No. of Pages

6

Main Subjects

Medicine

Abstract EN

It remains unclear which children and adolescents with resected nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) benefit from radiation therapy, as well as the optimal dose, volume, and timing of radiotherapy when used with primary surgical resection.

This paper reviews the sparse literature from clinical trials and retrospective studies of resected pediatric NRSTS to discern local recurrence rates in relationship to the use of radiation therapy.

American Psychological Association (APA)

Million, Lynn& Donaldson, Sarah S.. 2012. Resectable Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma : Which Patients Benefit from Adjuvant Radiation Therapy and How Much?. ISRN Oncology،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-464225

Modern Language Association (MLA)

Million, Lynn& Donaldson, Sarah S.. Resectable Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma : Which Patients Benefit from Adjuvant Radiation Therapy and How Much?. ISRN Oncology No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-464225

American Medical Association (AMA)

Million, Lynn& Donaldson, Sarah S.. Resectable Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma : Which Patients Benefit from Adjuvant Radiation Therapy and How Much?. ISRN Oncology. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-464225

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-464225